Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...

This health news roundup covers significant advances and alerts, including the approval of Bristol Myers' new schizophrenia ...

People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...

Jack Otter and the ‘Barron’s Roundtable’ panelists discuss how shareholders are continuing to have meetings virtually.

Hundreds of homes were flooded by Hurricane Helene's storm surge in the Tampa Bay metro. Hurricane Helene Leaves Huge Swaths ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...

Xanomeline and trospium chloride is a first-in-class medication that selectively targets the M1 and M4 receptors without blocking D2 receptors.

On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...

The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating ...

Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...

Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...